Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CASP6 | P55212 | 2/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6853137 | 0.98 | NOTUM (0.50) | NOTUMHPGDKMT2ACASP3CASP6 | |
| SCHEMBL24119472 | 0.85 | CYP1A2 (0.52) | NOTUMHPGDKMT2ACASP3CASP6 | |
| SCHEMBL12888750 | 0.84 | DRD2 (0.40) | NOTUMHPGDKMT2AOPRM1OPRK1 | |
| SCHEMBL12049027 | 0.83 | MEN1 (0.50) | NOTUMKMT2ATDP1OPRM1OPRK1 | |
| SCHEMBL13965463 | 0.82 | NOTUM (0.46) | NOTUMHPGDKMT2ACASP3CASP6 | |
| SCHEMBL3923485 | 0.81 | HPGD (0.50) | NOTUMHPGDKMT2ACASP3CASP6 | |
| SCHEMBL29601091 | 0.81 | HPGD (0.50) | NOTUMHPGDKMT2ACASP3CASP6 | |
| SCHEMBL24119281 | 0.79 | KMT2A (0.53) | NOTUMHPGDKMT2ACASP3CASP6 | |
| SCHEMBL14095571 | 0.79 | KMT2A (0.49) | NOTUMHPGDKMT2ACASP3CASP6 | |
| SCHEMBL22401868 | 0.78 | NOTUM (0.42) | NOTUMHPGDKMT2ACASP3CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| US-9994913-B2 | Methods and compositions for detecting and treating drug resistant AKT mutant | GENENTECH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180009808-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2018-01-11 | — | — | US | disclosed |
| US-9808457-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-9802935-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20170121348-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170121331-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20140031259-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-7473688-B2 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| US-7319100-B2 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070155740-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| US-7205306-B2 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009808-A1 | CGRP Receptor Antagonists | CALCRL, CALCR, VIPR1 | NOTUM 3684/4885HPGD 767/4885KMT2A 4571/4885 |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | NOTUM 1843/4885HPGD 734/4885KMT2A 3645/4885 |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | NOTUM 759/4885HPGD 217/4885KMT2A 2933/4885 |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | NOTUM 3881/4885HPGD 3055/4885KMT2A 3766/4885 |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | HTR3C, IDO1, HTR3B | NOTUM 1778/4885HPGD 3468/4885KMT2A 1730/4885 |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | PIK3R2, PIK3R1, AKT2 | NOTUM 4167/4885HPGD 3411/4885KMT2A 2895/4885 |
| US-20070155740-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | CRH, CRHR1, CRHR2 | NOTUM 4851/4885HPGD 747/4885KMT2A 4301/4885 |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | NOTUM 3881/4885HPGD 3055/4885KMT2A 3766/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | NOTUM 4162/4885HPGD 2775/4885KMT2A 2755/4885 |
| US-20170121331-A1 | CGRP Receptor Antagonists | CALCRL, CALCR, VIPR1 | NOTUM 3684/4885HPGD 767/4885KMT2A 4571/4885 |
| US-20170121348-A1 | CGRP Receptor Antagonists | CALCRL, CALCR, VIPR1 | NOTUM 3717/4885HPGD 836/4885KMT2A 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.